PriceTargets.com logo

CVE:DOC - CloudMD Software & Services Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$3.25
  • Forecasted Upside: 55.50 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$2.09 As of 03/5/2021 04:59 PM ET
▼ -0.05 (-2.34%)
1 month | 3 months | 12 months
Get New CloudMD Software & Services Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
C$3.25
▲ +55.50% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for CloudMD Software & Services in the last 3 months. The average price target is C$3.25, with a high forecast of C$4.00 and a low forecast of C$2.50. The average price target represents a 55.50% upside from the last price of C$2.09.
Buy
The current consensus among 2 polled investment analysts is to buy stock in CloudMD Software & Services. This rating has held steady since January 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/1/2021LaurentianSet Price TargetBuyC$4.00
i
9/22/2020Canaccord GenuityBoost Price TargetC$1.75 ➝ C$2.50
i
9/1/2020Canaccord GenuityBoost Price TargetC$1.30 ➝ C$1.75
i
8/25/2020Canaccord GenuityBoost Price TargetC$1.20 ➝ C$1.30
i
7/7/2020Echelon Wealth PartnersReiterated RatingSpeculative Buy
i
Rating by R. Goff at Echelon Wealth Partners
(Data available from 3/8/2016 forward)
CloudMD Software & Services logo
CloudMD Software & Services Inc., a technology company, provides SaaS based health technology solutions to medical clinics in Canada. The company provides digital technologies that connect doctors and allied health care providers to their patients. It also engages in retailing of prescription drugs, over-the-counter drugs, and other front store items through primary care clinics and pharmacies, as well as provide clinical, medical reviews, and compounding services. The company was formerly known as Premier Health Group Inc. and changed its name to CloudMD Software & Services Inc. in February 2020. CloudMD Software & Services Inc. was incorporated in 2013 and is headquartered in Victoria, Canada.
Read More

Today's Range

Now: C$2.09
C$1.85
C$2.20

50 Day Range

MA: C$2.58
C$2.14
C$3.14

52 Week Range

Now: C$2.09
C$0.37
C$3.43

Volume

4,950,859 shs

Average Volume

1,933,114 shs

Market Capitalization

C$350.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CloudMD Software & Services?

The following Wall Street sell-side analysts have issued stock ratings on CloudMD Software & Services in the last twelve months: Canaccord Genuity, Echelon Wealth Partners, and Laurentian.
View the latest analyst ratings for DOC.

What is the current price target for CloudMD Software & Services?

2 Wall Street analysts have set twelve-month price targets for CloudMD Software & Services in the last year. Their average twelve-month price target is C$3.25, suggesting a possible upside of 55.5%. Laurentian has the highest price target set, predicting DOC will reach C$4.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of C$2.50 for CloudMD Software & Services in the next year.
View the latest price targets for DOC.

What is the current consensus analyst rating for CloudMD Software & Services?

CloudMD Software & Services currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DOC will outperform the market and that investors should add to their positions of CloudMD Software & Services.
View the latest ratings for DOC.

What other companies compete with CloudMD Software & Services?

Other companies that are similar to CloudMD Software & Services include 1st Group, Alcidion Group, Binovi Technologies, Cann American, CannaOne Technologies, CloudMD Software & Services, Cogstate, Corum Group, EGF Theramed Health, Emyria Limited (EMD.AX), eWellness Healthcare, Global Health, ICS Global, Jayex Healthcare and M3.